Please assess the completion status of the following clinical trial:

Trial Title: Re-treatment of Participants With Paget's Disease Using Zoledronic Acid

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Written Informed Consent~* Participants with Paget's disease randomized to the zoledronic acid arm from the CZOL446K2304 and CZOL446K2305 core studies and who were responders by 6 months~* Confirmed relapse of Paget's disease of bone (i.e., serum alkaline phosphatase (SAP) above upper limit of normal (ULN), bone scan, worsening clinical symptoms)~Exclusion Criteria:~* A participant previously treated with zoledronic acid who relapsed and was retreated with anti-resorptive bisphosphonate or calcitonin therapy within the last 12 months~* Bisphosphonate Hypersensitivity~* Participants with suspected/proven metastases at re-treatment~* Calculated creatinine clearance \<35 milliliter/minute (mL/min) at screening~* Serum calcium level \<2.07 millimole/liter (mmol/L) at screening~* Active primary hyperparathyroidism, hyperparathyroidism, hypoparathyroidism or hypothyroidism~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Zoledronic Acid 5 mg (Type: EXPERIMENTAL): Participants received single re-treatment dose of zoledronic acid 5 mg intravenous (IV) infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).